Polycystic Ovarian Disease (PCOS) affects 5 to 10 percent of women in their reproductive years and is the most common abnormal endocrine problem that affects women. Stein and Leventhal first described PCOS in 1935. The disorder was characterized by the association between abnormal (anovulatory) menstruation and ovaries with multiple, large cysts. A recent review on the pathophysiology of PCOS by Tsilchorozido and co-workers describe the three main features of the disorder. The clinical features include menstrual abnormalities, hirsutism, acne, alopecia, anovulatory infertility and recurrent miscarriages. The endocrine features include elevated androgens, luteinizing hormone, estrogen and prolactin levels. The metabolic aspects of this syndrome include insulin resistance, obesity, lipid abnormalities and an increased risk for impaired glucose tolerance and type 2 diabetes mellitus. PCOS is a chronic state of high androgen production that has many significant short-term and long-term implications for patients such as infrequent or absent menstruation, infertility, abnormal glucose levels of frank Type 2 diabetes mellitus, cardiovascular disease, increased risk of endometrial cancer, and hirsutism. In 1990-because of new findings-experts convened during at the 2003 consensus workshop in Rotterdam, Netherlands. Those present concluded that PCOS is a syndrome of ovarian dysfunction along with the cardial features hyperandrogenism and polycystic ovary (PCO) morphology. The authors stated that PCOS remains a syndrome and, as such, no single diagnostic criterion (such as hyperandrogenism or PCO) is sufficient for clinical diagnosis.